Careteq Ltd. (CTQ) AI Stock Analysis

• Market Cap: N/A
• Dividend Yield: N/A
• Average Volume (3M): 282.90K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.95
• Revenue Growth: 5.42%
• EPS Growth: 97.46%
• Country: AU
• Employees: 24
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Healthcare Information Services
• EPS (TTM): 0.00
• Shares Outstanding: 237,118,710
• 10 Day Avg. Volume: 410,725
• 30 Day Avg. Volume: 282,903
• PEG Ratio: 0.54
• Price to Book (P/B): 2.61
• Price to Sales (P/S): 0.52
• P/FCF Ratio: -4.93
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 41 Neutral
• Price Target: AU$0.00 ▼(-100.00% Downside)

Careteq Ltd. faces significant financial challenges, with high leverage and negative cash flows being the most impactful factors. Technical indicators suggest weak momentum, and valuation metrics are unattractive due to ongoing losses. The company needs to improve financial stability and profitability to enhance its stock attractiveness.

Careteq Ltd. Business Overview & Revenue Model

Company Description

Careteq Ltd. (CTQ) is a leading provider of innovative healthcare technology solutions, specializing in the development and deployment of digital health platforms and medical devices. The company operates primarily in the healthcare sector, focusing on improving patient outcomes through advanced telemedicine services, remote patient monitoring systems, and electronic health record management. With a commitment to enhancing the efficiency of healthcare delivery, Careteq Ltd. offers a suite of products designed for healthcare providers, patients, and caregivers, ensuring seamless communication and data accessibility.

How the Company Makes Money

Careteq Ltd. generates revenue through multiple streams, including the sale of software licenses for its digital health platforms, subscription fees for ongoing services such as telemedicine and patient monitoring, and the sale of proprietary medical devices. The company also partners with healthcare institutions and insurance providers to integrate its solutions into existing systems, which provides additional revenue through service agreements and training programs. Moreover, Careteq Ltd. benefits from government grants and funding aimed at promoting digital health initiatives, further enhancing its financial sustainability.

Careteq Ltd. Financial Statement Overview

Summary

Careteq Ltd. is experiencing strong revenue growth, which is a positive sign for future potential. However, the company continues to face challenges with profitability, as evidenced by negative margins and net income. The balance sheet shows low leverage but declining equity, while cash flow statements highlight ongoing cash constraints. Overall, the company needs to improve operational efficiency and manage cash flows more effectively to achieve sustainable growth and profitability.

Income Statement

The company has shown significant revenue growth, with a 30.9% increase from 2023 to 2024. However, profitability remains a concern with negative net and gross profit margins. The net income margin is consistently negative, indicating ongoing losses. Despite an improvement in revenue, the company's EBIT and EBITDA margins are negative, reflecting challenges in operational efficiency and profitability.

Balance Sheet

The balance sheet shows a moderate debt-to-equity ratio with low total debt, which suggests limited leverage and potential stability. However, the company's equity has decreased over time, reducing the equity ratio. The return on equity is negative due to net losses, indicating that the company is not generating profits from shareholders' equity.

Cash Flow

The company is facing negative free cash flow, although there is a slight improvement in operating cash flow compared to the previous year. The free cash flow to net income ratio is unfavorable, indicating cash flow challenges. The financing cash flow is positive, suggesting reliance on external funding to support operations.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	7.62M	7.62M	7.23M	4.98M	4.43M	735.44K
Gross Profit	1.50M	1.50M	6.74M	-2.44M	4.14M	-2.03M
EBITDA	275.62K	275.62K	-826.62K	-2.65M	-5.90M	-5.06M
Net Income	-72.20K	-72.20K	-2.67M	-4.33M	-5.25M	-5.23M
Balance Sheet
Total Assets	5.94M	5.94M	6.82M	7.57M	8.02M	12.23M
Cash, Cash Equivalents and Short-Term Investments	1.05M	1.05M	1.25M	1.85M	4.50M	8.90M
Total Debt	2.37M	2.37M	192.98K	961.96K	0.00	75.28K
Total Liabilities	4.42M	4.42M	3.30M	4.02M	1.72M	2.61M
Stockholders Equity	1.52M	1.52M	1.97M	2.14M	6.30M	9.61M
Cash Flow
Free Cash Flow	-804.93K	-804.93K	-2.59M	-3.42M	-4.54M	-1.52M
Operating Cash Flow	-732.06K	-732.06K	-1.30M	-2.53M	-4.52M	-1.50M
Investing Cash Flow	119.16K	119.16K	-570.80K	-799.63K	-256.83K	-23.21K
Financing Cash Flow	370.14K	400.96K	1.27M	687.55K	8.81M	1.50M

Careteq Ltd. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.01
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:CTQ, the sentiment is Negative. The current price of 0.01 is below the 20-day moving average (MA) of 0.01, below the 50-day MA of 0.01, and below the 200-day MA of 0.01, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 36.48 is Neutral, neither overbought nor oversold. The STOCH value of >-0.01 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:CTQ.

Careteq Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PCK	55 Neutral	AU$122.28M	―	-8647.54%	―	25.98%	21.43%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
CTQ	41 Neutral	―	―	3.02%	―	5.42%	97.46%
GLH	40 Neutral	AU$5.87M	―	―	―	-9.90%	34.07%
SHG	40 Underperform	AU$89.08M	―	―	―	―	―
MDR	38 Underperform	AU$17.71M	110.00	-240.60%	―	-48.41%	-7200.00%
ICR	34 Underperform	AU$15.85M	―	―	―	241.34%	44.19%

Careteq Ltd. Corporate Events

Careteq Limited Announces Director’s Interest Change

Careteq Limited has announced a change in the director’s interest notice, specifically regarding Mark Simari. The company disclosed that 3,000,000 unlisted options held indirectly by Simari through Charkaroo Pty Ltd have expired, with no new acquisitions or disposals of other securities reported. This change signifies a reduction in potential future equity for the director, which may impact his financial stake in the company.

Careteq Ltd. Issues Unlisted Convertible Notes

Careteq Ltd. announced the issuance of 355,678 unlisted convertible notes, marking a strategic financial move to potentially enhance its capital structure. This issuance is expected to impact the company’s financial flexibility and could influence its market positioning by providing additional resources for growth and development.

Careteq Limited Addresses Breach of ASX Listing Rule with Remedial Actions

Careteq Limited has acknowledged a breach of ASX Listing Rule 7.1 due to an incorrect issuance of convertible notes, exceeding its placement capacity. The company has taken remedial actions by amending the agreement and will seek shareholder approval for the excess issuance, reaffirming its commitment to compliance and corporate governance.

Careteq Limited Secures $625,000 in Funding to Strengthen Financial Position

Careteq Limited has secured a $500,000 convertible note from investor and entrepreneur Antanas Guoga to bolster its working capital. Additionally, the company’s board members have contributed $125,000 through a loan agreement, bringing the total raised to $625,000. This funding positions Careteq well for medium-term financial stability and reflects confidence in its strategic direction and market potential.

Careteq Disputes ATO’s Amended R&D Tax Assessments

Careteq Limited has received amended assessments from the Australian Taxation Office regarding its R&D Tax Incentive claims for the financial years ending in 2021, 2022, and 2023, requiring repayment of refunds and interest. The company disputes these assessments and plans to formally object, maintaining confidence in the eligibility of its R&D activities and the validity of its claims, and will engage with the ATO throughout the objection process.

Careteq Ltd. Announces Cessation of Securities

Careteq Ltd. announced the cessation of 2,000,000 securities due to the expiry of options or other convertible securities without exercise or conversion as of May 6, 2025. This cessation of securities may impact the company’s capital structure and could have implications for its financial strategies and stakeholder interests.